Interactions | Patients n = 624 n (%) |
---|---|
Potential drug-drug interactions | 492 (78.8) |
Number of potential drug-drug interactions* | |
1 | 154 (24.7) |
2 | 92 (14.7) |
3–4 | 154 (24.7) |
≥ 5 | 92 (14.7) |
Type D | 24 (3.8) |
ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation) | 11 (1.8) |
NSAID*+ Methotrexate | 5 (0.8) |
NSAID* +anticoagulants (or glucocorticoids) | 5 (0.8) |
β blocking agents + Verapamil (or Fluoxetin) | 3 (0.4) |
Type C | 468 (75.0) |
ACE* inhibitors + NSAID* | 252 (40.4) |
NSAID*+ low dose ASA* | 212 (34.0) |
NSAID*+ sulfonylureas | 128 (20.5) |
ACE* inhibitors + low dose ASA* | 130 (20.8) |
β blocking agents + NSAID* | 107 (17.1) |
NSAID* + Diuretics | 105 (16.8) |
ACE* inhibitors + glybenclamide | 68 (10.9) |
NSAID*+ other NSAID* | 51 (8.2) |
ACE* inhibitors + thiazide diuretics | 47 (7.6) |
Pravastatin + bezafibrate | 35 (5.6) |
Pentoxiyilline + antihypertensives | 37 (5.9) |
Metformin+ ranitidine | 40 (6.5) |
Glibenclamide + antimycotics or cotrimoxazole | 24 (3.9) |
Furosemide + ACE* inhibitors | 21 (3.4) |
ACE* inhibitors + antiacids | 19 (3.1) |
Alendronate + NSAIDs* | 18 (2.9) |
Insulin + antihypertensive | 18 (2.9) |
Pentoxifylline + hypoglycemic agents | 14 (2.2) |
Acetaminophen + carbamazepin | 14 (2.2) |
Ranitidine + azole type of antimycotics | 11 (1.8) |
Others | 61 (9.4) |
Potential drug-disease interactions | 400 (64.1) |
Number of potential drug-disease interactions | |
1 | 346 (55.4) |
≥ 2 | 54 (8.7) |
NSAIDs* in patients with hypertension and/or chronic heart failure | 384 (61.5) |
β blocking agents in patients with diabetes mellitus | 31 (5.0) |
NSAIDs* in patients with chronic renal insufficiency | 18 (2.9) |
NSAIDs* in patients with previous peptic ulcer | 8 (1.3) |
Thiazides diuretics in patients with gout | 7 (1.1) |
Metformin in patients with chronic renal insufficiency or congestive heart failure | 6 (1.0) |
β blocking agents in patients with peripheral vascular disease | 4 (0.6) |
β blocking agents in patients with asthma/COPD* | 3 (0.5) |
Others | 5 (1.0) |